New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
04:55 EDTAET, AET, AET, RNA, RNA, RNA, SHPG, SHPG, SHPG, ALXN, ALXN, ALXN, MSTX, MSTX, MSTX, NVS, NVS, NVS, SRPT, SRPT, SRPT, GENZ, GENZ, GENZ, FOLD, FOLD, FOLD, RXII, RXII, RXII, PFE, PFE, PFE, HUM, HUM, HUMTerrapinn to hold a conference
World Orphan Drug Congress is being held in Washington, D.C. on April 23-25.
News For HUM;PFE;RXII;FOLD;GENZ;SRPT;NVS;MSTX;ALXN;SHPG;RNA;AET From The Last 14 Days
Check below for free stories on HUM;PFE;RXII;FOLD;GENZ;SRPT;NVS;MSTX;ALXN;SHPG;RNA;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2014
08:01 EDTALXNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTPFE, SHPGTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
05:53 EDTSHPGStocks with implied volatility below IV index mean; LO SHPG
Stocks with implied volatility below IV index mean; Lorillard (LO) 21, Shire (SHPG) 31 according to iVolatility.
05:47 EDTSHPGStocks with implied volatility movement; SHPG XLP
Subscribe for More Information
July 15, 2014
10:37 EDTSHPGOptions with decreasing implied volatility
Subscribe for More Information
06:04 EDTSHPGStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:44 EDTNVSNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
05:35 EDTNVSNovartis collaborates with Banner Alzheimer's Institute on study
Novartis announced a collaboration with Banner Alzheimer's Institute, or BAI, on a pioneering clinical study in Alzheimer's disease, or AD, prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease. Using an innovative trial design, the two treatments will be given in cognitively healthy people at genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to AD. One treatment is an active immunotherapy, a treatment that stimulates an immune response, and triggers the production of natural antibodies against amyloid. This investigational treatment, given via an injection, is in phase II clinical development. The second treatment, a BACE inhibitor, is an oral medication about to enter phase I trials and is designed to prevent the production of different forms of amyloid.
July 14, 2014
16:30 EDTSHPGOn The Fly: Closing Wrap
Subscribe for More Information
16:18 EDTSHPGShire shareholders should support latest AbbVie offer, Telegraph says
Subscribe for More Information
16:15 EDTHUMHumana, Tenet sign new multi-year national agreement
Subscribe for More Information
10:00 EDTSHPGOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
09:55 EDTSHPGHigh option volume stocks: PTEN MFRM GTIV SHPG IMMR
09:16 EDTSHPGOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
07:23 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
07:22 EDTHUMHealthcare Education Associates to hold a conference
4th Annual RISE California Summit to be held in San Diego on July 13-15.
06:03 EDTSHPGStocks with implied volatility below IV index mean; BBBY SHPG
Subscribe for More Information
05:27 EDTSHPGShire receives revised proposal from AbbVie of GPB 53.20 per share
Subscribe for More Information
July 13, 2014
17:10 EDTSHPGShire said to seek bid of near 53 pounds per share from AbbVie, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use